君实生物子公司苏州众合通过FDA现场检查

Core Viewpoint - Junshi Biosciences (688180.SH) announced that its wholly-owned subsidiary, Suzhou Zhonghe Biopharmaceutical Technology Co., Ltd. (referred to as "Suzhou Zhonghe"), successfully passed a CGMP (Current Good Manufacturing Practice) inspection by the FDA from June 16 to June 24, 2025, indicating ongoing international recognition of the company's high-quality manufacturing system [1]. Group 1 - Suzhou Zhonghe received the FDA's Establishment Inspection Report (EIR), confirming compliance with CGMP standards [1]. - This marks the second successful FDA inspection for Suzhou Zhonghe since it first passed in 2023, demonstrating the company's commitment to maintaining high production quality [1].